Neurodegenerative Disorder News and Research RSS Feed - Neurodegenerative Disorder News and Research

Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

Harvard stem cell scientists discover potential treatment for amyotrophic lateral sclerosis

Harvard stem cell scientists have discovered that a recently approved medication for epilepsy may possibly be a meaningful treatment for amyotrophic lateral sclerosis (ALS)-Lou Gehrig's disease, a uniformly fatal neurodegenerative disorder. The researchers are now collaborating with Massachusetts General Hospital to design an initial clinical trial testing the safety of the treatment in ALS patients. [More]
UCSF/Daiichi Sankyo establish drug-discovery collaboration focused on neurodegenerative diseases

UCSF/Daiichi Sankyo establish drug-discovery collaboration focused on neurodegenerative diseases

Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and UC San Francisco (UCSF) announced today that they have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases. [More]
Parkinson disease patients with higher CSF experience faster cognitive decline

Parkinson disease patients with higher CSF experience faster cognitive decline

Counterintuitive Findings Offer New Insights into Parkinson Disease Pathology, According to New Research Published in The American Journal of Pathology [More]
High-carbohydrate, high-calorie diet could delay progression of Amyotrophic Lateral Sclerosis

High-carbohydrate, high-calorie diet could delay progression of Amyotrophic Lateral Sclerosis

A high-carbohydrate, high-calorie diet could delay the progression of Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease or Lou Gehrig’s disease, according to a phase 2 study published in The Lancet. [More]

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD. [More]

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS). [More]
Study offers new avenue to pursue in quest for desperately needed treatments for ALS

Study offers new avenue to pursue in quest for desperately needed treatments for ALS

St. Jude Children's Research Hospital scientists led a study showing that mutations in a gene responsible for amyotrophic lateral sclerosis (ALS) disrupt the RNA transport system in nerve cells. [More]
UC San Diego researchers uncover causes for hereditary spastic paraplegia

UC San Diego researchers uncover causes for hereditary spastic paraplegia

In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features. [More]

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease. [More]
Study links discrete area of brain to cognitive deficit in people at early stage of PD

Study links discrete area of brain to cognitive deficit in people at early stage of PD

Research by a team of investigators in Finland suggests that the free recall memory deficits common even in early stages Parkinson's disease (PD) are related to structural changes in the brain, specifically parietal cortical gray matter volume. [More]
Higher vitamin D levels linked with better cognition and less depression in PD patients

Higher vitamin D levels linked with better cognition and less depression in PD patients

A new study exploring vitamin D levels in patients with Parkinson's disease (PD) opens up the possibility of a new avenue of early intervention that may delay or prevent the onset of cognitive impairment and depression. The findings are published in the Journal of Parkinson's Disease. [More]

Study links a discrete area of the brain to cognitive deficit in people at early stage of PD

Research by a team of investigators in Finland suggests that the free recall memory deficits common even in early stages Parkinson's disease are related to structural changes in the brain, specifically parietal cortical gray matter volume. Their findings are published in the current issue of the Journal of Parkinson's Disease. [More]
Research: New target for treating Huntington's and Parkinson's disease

Research: New target for treating Huntington's and Parkinson's disease

Research from Western University (London, Canada) has revealed a possible new target for treating movement disorders such as Huntington's disease (HD) and Parkinson's disease. Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a HD mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted. [More]
Research: Creuztfeldt-Jakob disease might be transmitted by blood transfusion

Research: Creuztfeldt-Jakob disease might be transmitted by blood transfusion

Creuztfeldt-Jakob disease (CJD) is a rare but fatal disease in humans. For the first time, the presence of infectivity[1] in the blood of patients affected by sporadic and the new variant of CJD was established by scientists from the French National Institute for Agricultural Research (INRA) and the French National Veterinary School (ENVT), in collaboration with European partners. [More]
Exercise program improves symptoms of depression in patients with Parkinson's disease

Exercise program improves symptoms of depression in patients with Parkinson's disease

A new study by a movement disorder neurologist at The Ohio State University Wexner Medical Center found that depression improved among patients with Parkinson's disease who participated in a long-term group exercise program. [More]
Scientists identify enzyme that could lead to better treatment of Alzheimer's disease

Scientists identify enzyme that could lead to better treatment of Alzheimer's disease

St. Jude Children's Research Hospital scientists have identified an enzyme that can halt or possibly even reverse the build-up of toxic protein fragments known as plaques in the brains of mice with Alzheimer's disease. The research appeared in a recent edition of the scientific journal Nature Communications. [More]
Mutation in alpha-synuclein gene causes increased vulnerability to pesticides, leading to Parkinson's

Mutation in alpha-synuclein gene causes increased vulnerability to pesticides, leading to Parkinson's

​A team of researchers has brought new clarity to the picture of how gene-environmental interactions can kill nerve cells that make dopamine. Dopamine is the neurotransmitter that sends messages to the part of the brain that controls movement and coordination. [More]
Biochemical signal in blood is associated with faster-progressing form of Parkinson's

Biochemical signal in blood is associated with faster-progressing form of Parkinson's

​The physical decline experienced by Parkinson's disease patients eventually leads to disability and a lower quality of life. Depending on the individual, the disorder can progress rapidly or slowly. [More]

Rugby star partners with researchers to tackle motor neurone disease

A World Cup winning rugby star is joining forces with leading researchers in a new partnership to tackle motor neurone disease (MND). [More]

Researchers use new approach to parse roles of key mutated protein that causes familial AD

Researchers at the University of California, San Diego School of Medicine have used genetic engineering of human induced pluripotent stem cells to specifically and precisely parse the roles of a key mutated protein in causing familial Alzheimer's disease, discovering that simple loss-of-function does not contribute to the inherited form of the neurodegenerative disorder. [More]